Linked Articles This article is part of a themed issue on Cannabinoids in Biology and Medicine. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue-7
Themed issue on cannabinoids in biology and medicine
Version of Record online: 12 JUL 2011
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society
British Journal of Pharmacology
Special Issue: Cannabinoids in Biology and Medicine, Part I. Guest Editors: Itai Bab and Steve Alexander
Volume 163, Issue 7, pages 1327–1328, August 2011
How to Cite
Bab, I. (2011), Themed issue on cannabinoids in biology and medicine. British Journal of Pharmacology, 163: 1327–1328. doi: 10.1111/j.1476-5381.2011.01536.x
- Issue online: 12 JUL 2011
- Version of Record online: 12 JUL 2011
- cannabinoid receptors;
- endocannabinoid metabolizing enzymes
Current cannabinoid research is based on a number of major discoveries made by Professor Raphael Mechoulam. In the mid-1960s, he, together with Professor Yechiel Gaoni, identified in the plant Cannabis sativa, the psychoactive component of marijuana and hashish, Δ9-tetrahydrocannabinol (THC), determined its chemical structure (Gaoni and Mechoulam, 1964; Mechoulam and Gaoni, 1967) and synthesized it (Mechoulam et al., 1967). The pertussis toxin-sensitive inhibition of adenylate cyclase activity by THC and related synthetic cannabimimetic compounds, such as desacetyllevonantradol (Howlett, 1985), led a couple of decades later to the cloning of the first cannabinoid receptor (CB1) in neural cell lines and several regions of the brain (Matsuda et al., 1990). Reasoning that this receptor is targeted by an endogenous component(s), Professor Mechoulam made his second major breakthrough, the discovery of ligands for this receptor, arachidonyl ethanolamide (anandamide) (Devane et al., 1992) and 2-arachidonyglycerol (Mechoulam et al., 1995), thus establishing the presence of the endocannabinoid system. These discoveries were followed by cloning of another, predominantly peripheral cannabinoid receptor (CB2) (Munro et al., 1993) and the endocannabinoid metabolizing enzymes diacylglycerol lipases, NAPE-selective phospholipase D, monoacylglycerol lipase and fatty acid amide hydrolase (Ligresti et al., 2005; McKinney and Cravatt, 2005).
Professor Mechoulam's discoveries have led to a wealth of basic, translational and clinical studies. It is now well established that endocannabinoids regulate a handful of central and peripheral pathophysiologic functions. Furthermore, cannabinoid ligands and enzyme inhibitors of the endocannabinoid degrading enzymes hold great promise for treating several pathological conditions. In fact, a cannabinoid medicine consisting of THC and another phytocannabinoid, cannabidiol (CBD), has made its way to the clinic as a treatment of spasticity due to multiple sclerosis and for cancer and neuropathic pain. Academically, the field of cannabinoid research generates a huge number of articles, with a current annual rate higher than 10 000. A substantial number of these articles have been published in journals of the highest impact factor.
The present BJP Themed Issues bring together reviews summarizing an international workshop, entitled ‘Cannabinoids in Biology and Medicine’, convened in Jerusalem in October 2010 to celebrate Professor Mechoulam's 80th birthday and acknowledge his past and ongoing contributions to the field of cannabinoid research. These reviews describe a range of topics in the cannabinoid arena. A couple of them focus on the mode of receptor activation by cannabinoid ligands. One of them addresses the issue of endocannabinoid tone versus constitutive activity of cannabinoid receptors, concluding that receptor activation in the absence of agonist ligands is rather unlikely (Howlett et al., 2011). The other article explores the pharmacological activity and therapeutic potential of phytoterpenoids (Russo, 2011).
Being historically based on the psychoactivity of marijuana and hashish, cannabinoid research has had its main focus on pathophysiology of the central nervous system. Indeed, almost half of the present reviews deal with topics related to the role of cannabinoids in brain disorders. The potential therapeutic role of CB1 and CB2 ligands in neurodegenerative and neuroinflammatory disorders is covered, as well as possible mechanisms associated with the activation of CB1 and CB2 in these instances (Fernández-Ruiz et al., 2011; Maccarrone et al., 2011). The neuroprotective effect of cannabinoid ligands is discussed versus their potential neurotoxicity (Sarne et al., 2011). The neuroprotective activity of the endocannabinoid system, especially after traumatic brain injury, is further addressed in view of the involvement of both CB1 and CB2 receptors in this condition (Shohami et al., 2011). Mechanisms involved in the anti-nausea effects of anandamide and the non-psychoactive phytocannabinoid, CBD, are highlighted based on recent findings pointing towards activation of the serotonergic system by CBD (Parker et al., 2011).
Extensive research has been carried out, especially in the past decade, on the peripheral functions of the endocannabinoid system. This Themed Issue underlines the role of CB1 and endocannabinoids in pathophysiology of the metabolic syndrome, with a special emphasis on the potential therapeutic role of peripherally selective CB1 antagonists (Kunos and Tam, 2011). A related article broadens this spectrum by further discussing the prospects of treating chronic liver disease with CB1 antagonists and CB2 agonists (Mallat et al., 2011). The skeletal cannabinoid system is portrayed as part of the larger family of fatty acid amides, recently implicated in the regulation of skeletal remodelling and bone mass (Bab et al., 2011).
Another review examines how activation of the endocannabinoid system impacts breast, prostate and bone malignancies in in vitro and in vivo models, including the therapeutic potential of cannabinoids for cancer, as identified in clinical trials (Guindon and Hohmann, 2011). Last but not least, a summary of 18 clinical trials assessing the analgesic effects of different phytocannabinoid preparations in instances of chronic non-cancer pain is reviewed. The important message is that cannabinoids are safe and modestly effective, particularly in neuropathic pain (Lynch and Campbell, 2011).
In addition to these review articles, the two Themed Issues hold 26 exciting research articles on the molecular, cellular, tissue and whole animal aspects of cannabinoid activities. Several of them report novel interactions of the endocannabinoid system with other biological processes. These papers illustrate the rapidly expanding cannabinoid research field that encompasses a broad spectrum of physiological and pathophysiological mechanisms in diverse cell types. Hopefully, these Themed Issues deepen and expand our knowledge and understanding of the biological actions of cannabinoids and their medical significance.
Steve Alexander acted as co-guest editor during the preparation of this issue.
Conflict of interest
The author states no conflict of interest.
- 2011). Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 163: 1441–1446. , , , (
- 1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949. , , , , , et al. (
- 2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163: 1365–1378. , , , , , et al. (
- 1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646–1647. , (
- 2011). The endocannabinoid system and cancer: therapeutic implications. Br J Pharmacol 163: 1447–1463. , (
- 1985). Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27: 429–436. (
- 2011). Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 163: 1329–1343. , , , , , (
- 2011). The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163: 1423–1431. , (
- 2005). Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord 4: 615–623. , , (
- 2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol DOI: 10.1111/j.1365-2125.2011.03970.x. , (
- 2005). Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74: 411–432. , (
- 2011). Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. Br J Pharmacol 163: 1379–1390. , , , (
- 2011). The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 163: 1432–1440. , , , , (
- 1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564. , , , , (
- 1967). The absolute configuration of Δ1-tetra- hydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12: 1109–1111. , (
- 1967). A stereospecific synthesis of (-)-Δ1 and (-)-Δ6-tetrahydrocannabinols. J Am Chem Soc 89: 4552–4554. , , (
- 1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90. , , , , , et al. (
- 1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65. , , (
- 2011). Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 163: 1411–1422. , , (
- 2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344–1364. (
- 2011). The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol 163: 1391–1401. , , , , (
- 2011). Endocannabinoids and traumatic brain injury. Br J Pharmacol 163: 1402–1410. , , , , (